

## Circulating plasma cytokines, zinc, copper, vitamins A and E in multiple sclerosis patients and healthy controls

L. S. Harbige<sup>1</sup>, E. Pinto<sup>1</sup>, M. Xiang<sup>1</sup> and M. K. Shareif<sup>2</sup>

<sup>1</sup>Centre for Biosciences Research, School of Science, University of Greenwich, Kent ME4 4TB, UK and <sup>2</sup>Department of Neurology, Colchester Hospital, Colchester, Essex CO4 5JL, UK

Previous reports including our own have shown low levels of vitamins E and A<sup>(1,2)</sup> increased or decreased Zn and Cu<sup>(3–5)</sup> and elevated pro-inflammatory cytokines<sup>(6–8)</sup> in the blood and CSF of multiple sclerosis (MS) patients. The aim of this study was to investigate the relationships between the levels of circulating plasma vitamins E and A, Zn, Cu, interferon- $\gamma$  (IFN $\gamma$ ), TNF $\alpha$  and IL-6 in MS patients in the remission phase of the disease compared with healthy controls. IFN $\gamma$ , TNF $\alpha$  and IL-6 were assayed using commercially available paired antibodies (Genzyme Diagnostics Inc., UK) in an ELISA format. Vitamins A and E were extracted in ethanol and determined using HPLC (Philips PU 4100) equipped with a PU 4110 UV/visible detector and C18 reverse phase column. Determination of Cu and Zn was by ICP-MS (Perkin Elmer 5000 ICP-MS). There was no significant difference in the mean plasma levels of vitamin A, Zn, Cu, IFN $\gamma$ , TNF $\alpha$  and IL-6 between MS patients and healthy controls (Table). There was, however, a significantly ( $P < 0.001$ ) lower plasma vitamin E concentration in patients with MS compared with controls and the mean concentrations of IFN $\gamma$ , TNF $\alpha$ , IL-6 and copper were elevated compared with healthy controls (Table).

	Retinol ( $\mu\text{g/l}$ )	$\alpha$ -Tocopherol (mg/l)	Cu ( $\mu\text{g/l}$ )	Zn ( $\mu\text{g/l}$ )	IFN $\gamma$ (pg/ml)	TNF $\alpha$ (pg/ml)	IL-6 (pg/ml)
MS	622 $\pm$ 69	10.2 $\pm$ 0.7*	1119 $\pm$ 309	884 $\pm$ 162	236 $\pm$ 498	144 $\pm$ 230	1299 $\pm$ 1723
HC	673 $\pm$ 84	11.2 $\pm$ 0.8	957 $\pm$ 189	858 $\pm$ 131	187 $\pm$ 90	40 $\pm$ 26	397 $\pm$ 775

MS, multiple sclerosis patients  $n$  21 aged 22–68 years with relapse-remitting disease (expanded disability status score 2–4.5) TNF- $\alpha$  ( $n$  16), IL-6 ( $n$  8); HC, healthy controls ( $n$  9) aged 25–45, IL-6 ( $n$  4). \* $P < 0.001$ .

Plasma vitamins A and E were positively correlated ( $P < 0.03$ ,  $r = 0.46$ ) in MS patients and in healthy controls ( $P < 0.04$ ,  $r = 0.6$ ). In MS patients only, a positive correlation between plasma IFN $\gamma$  and TNF $\alpha$  ( $P < 0.0001$ ,  $r = 0.91$ ) and also between Zn and vitamin A ( $P < 0.07$ ,  $r = 0.4$ ) was observed as well as a negative correlation between Zn and IL-6 ( $P < 0.07$ ,  $r = 0.64$ ). These findings suggest that pro-inflammatory cytokines such as IL-6 may be responsible, in part, for some of the previously observed alterations in circulating nutrients in patients with MS, i.e. Zn and vitamin A. The low plasma vitamin E finding in MS compared with controls is consistent with our earlier observations in MS<sup>(1)</sup> although the present values were higher both in controls (1.7-fold) and MS (1.8-fold) than we previously reported which may indicate an increase in the intake of vitamin E in the general and MS population since the original study. Moreover, vitamin E is an important membrane lipid antioxidant and given the importance of PUFA in MS<sup>(9)</sup> it should be further investigated in patients with MS both in remission and relapse phases of the disease and in relation to membrane PUFA.

1. Ghebremeskel K, Williams G, Harbige L *et al.* (1988) *J Clin Biochem Nutr* **5**, 81–85.
2. Jimenez-Jimenez F *et al.* (1998) *Neurosci Lett* **264**, 65–67.
3. Palm R & Hallmans G (1982) *J Neurol Neurosurg Psychiatry* **45**, 691–698.
4. Dore-Duffy P *et al.* (1983) *Ann Neurol* **14**, 450–454.
5. Kapaki E *et al.* (1989) *Acta Neurol Scand* **79**, 373–376.
6. Beck J *et al.* (1988) *Acta Neurol Scand* **78**, 318–323.
7. Sharief M & Thompson E (1992) *J Neuroimmunol* **38**, 27–33.
8. Hollifield R, Harbige L, Pham-Dinh D *et al.* (2003) *Autoimmunity* **36**, 133–141.
9. Harbige L & Sharief (2007) *Br J Nutr* **98**, 46–53.